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Abstract  
Neonatal anoxia-ischemia (AI) particularly affects the central nervous system. Despite the many 
treatments that have been tested, none of them has proven to be completely successful. 
Palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are acylethanolamides that do not bind 
to CB1 or CB2 receptors and thus they do not present cannabinoid activity. These molecules are 
agonist compounds of peroxisome proliferator-activator receptor alpha (PPARα), which modulates the 
expression of different genes that are related to glucose and lipid metabolism, inflammation, 
differentiation and proliferation. In the present study, we analyzed the effects that the administration of 
PEA or OEA, after a neonatal AI event, has over different areas of the hippocampus. To this end, 7-
day-old rats were subjected to AI and then treated with vehicle, OEA (2 or 10 mg/kg) or PEA (2 or 10 
mg/kg). At 30 days of age, animals were subjected to behavioral tests followed by 
immunohistochemical studies. Results showed that neonatal AI was associated with decreased 
locomotion, as well as recognition and spatial memory impairments. Furthermore, these deficits were 
accompanied with enhanced neuroinflammation and astrogliosis, as well as a decreased PPARα 
expression. PEA treatment was able to prevent neuroinflammation, reduce astrogliosis and preserve 
cognitive functions. These results indicate that the acylethanolamide PEA may play an important role 
in the mechanisms underlying neonatal AI, and it could be a good candidate for further studies 
regarding neonatal AI treatments 
Keywords: Neonatal anoxia-ischemia; Palmitoylethanolamide; Oleoylethanolamide; 
Neuroinflammation; Astrogliosis; Memory impairment 
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1. Introduction 
Neonatal hypoxia ischemia (HI) is an event that is usually triggered during birth. Either fetus 
lung malfunction or modifications in the placental gas exchange can lead to low levels of oxygen 
(hypoxia or anoxia) or a diminished blood flow (ischemia) in the fetus (Blanco et al. 2015; Carrera 
2006). Neonatal HI particularly affects the central nervous system (CNS) (Kumar et al. 2007), which is 
highly susceptible to oxidative stress, in part due to the elevated concentration of fatty acids present 
in this tissue (Halliwel, 1992). So far, hypothermia has been the only treatment that was able to 
consistently prevent the neurological damage and sequels associated to neonatal HI (Mishima et al. 
2004; Sebetseba et al. 2017). Neonatal HI is associated to learning and memory impairments (Blanco 
et al. 2015; Galeano et al. 2011, 2015; Takada et al. 2016). Mainly, it has shown to cause several 
cellular and molecular modifications in the hippocampus, including astrogliosis and focal swelling, 
among others (Blanco et al. 2015; Saraceno et al. 2010, 2012). 
The endogenous cannabinoids system (ECS) includes different enzymes responsible for 
endocannabinoid synthesis, transport and degradation, as well as endocannabinoids and 
endocannabinoid receptors (Ueda et al. 2013). The ECS is important for its regulation over different 
neurological and physiological processes, that include neural development, synaptic plasticity, reward 
processing, learning processes, neurogenesis and embryonic cell fate in the developing brain, 
through the activation of cannabinoid receptors 1 (CB1) and 2 (CB2) (Ahmad and Laviolette 2017; 
Alonso-Alconada et al. 2011; Blanco-Calvo et al. 2014; Serrano et al. 2012; Schoch et al. 2018; Ueda 
et al. 2013; Zhou et al. 2017). 
Endocannabinoids are produced from membrane phospholipids depending on cell demand, 
and they are soon degraded by the corresponding enzyme. These compounds are divided into two 
groups of fatty acid derivatives that present specific structures: acylethanolamides (AEs) and 
monoacylglycerols (MAGs) (Hansen and Diep 2009; Serrano et al. 2012; Ueda et al. 2013). To the 
date, the further characterized endocannabinoids are arachidonoyethanolamide (AEA, an AE also 
known as anandamide) and 2-arachidonoyglycerol (2AG, a MAG). AEs are synthesized from 
glycerophospholipids and degraded by the fatty acid amide hydrolase (FAAH) (Okamoto et al. 2009; 
Pasquarelli et al. 2015; Ueda et al. 2013). Other ethanolamine and palmitic acid amides such as 
palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are AEs that share both biosynthetic and 
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degradative pathways with AEA. However, these amides do not bind to CB1 and CB2 and thus they 
do not present cannabinoid activity (Fu et al. 2003; Scuderi et al. 2011). These molecules have been 
described as agonist of peroxisome proliferator-activator receptor alpha (PPARα), which is expressed 
in microvascular, neuronal and glial tissues, and plays a key role in glucose and lipid metabolism, 
inflammation, differentiation and proliferation (Cristiano et al. 2005; Xu et al. 2006). Furthermore, this 
receptor has been shown to play a key role as a neuroprotectant in different disorders (Bhateja et al. 
2012; Bordet et al. 2006; Moran et al. 2014). 
In previous works it has been shown that OEA and PEA present neuroprotective effects in 
cerebral ischemia (Ahmad et al. 2012; Naccarato et al. 2010; Yang et al. 2015; Zhou et al. 2012). 
Moreover, former studies from our group have shown diminished PPARα levels in hippocampus and 
striatum of animals that had been exposed to perinatal asphyxia (Blanco et al. 2015; Holubiec et al. 
2017). In the present study we aimed to analyze the effect that the administration of both PEA and 
OEA, after a neonatal anoxic-ischemic (AI) event, has over different areas of the hippocampus. To 
this purpose, the expression of different markers (Iba-1, GFAP and PPARα) was studied and an array 
of behavioral tests was performed. 
2. Materials and methods 
2.1. Experimental subjects 
Experiments in this study were performed in accordance with the ARRIVE (Animal Research: 
Reporting of In Vivo Experiments) and following the standards disposed by the European Directive 
2010/63/EU and the Spanish Royal Decree 53/2013 on the protection of animals used for research 
and other scientific purposes. All experiments (including the used of experimental animals) were 
approved by the ethic committee “Comité de Ética e Investigación Biosanitaria” of the IBIMA and 
University of Málaga. Female Sprague Dawley pregnant rats were kept in a vivarium under standard 
controlled conditions (temperature: 21 ± 2 °C; humidity: 65 ± 5 %; dark/light cycle: 12 h /12 h), and 
were supplied with ad libitum access to food (Purina chow) and tap water. Twenty-one days after the 
delivery date, pups were removed from their dams and housed in cages of four animals each under 
the same standard conditions as mentioned for the pregnant animals. Only male pups were selected 
to perform the present study. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
6 
 
2.2. Common carotid artery ligation and anoxia procedures 
The neonatal anoxia-ischemia model that was used in the present study has been already 
validated (Lopez-Aguilera et al. 2012; Romero et al. 2015, 2017). Dams were monitored daily in order 
to determine the exact date of birth of the pups. When the animals were 7 days old (P7), males were 
selected to be subjected to carotid artery ligation. Pups were anesthetized using a mixture of 40 
mg/kg ketamine and 4 mg/kg xylazine in order to also produce analgesia. When the animals were 
ready they were placed in a heated pad to prevent their body temperature from dropping below 37 °C. 
The area to be operated on was properly disinfected and an incision was made in order to reach the 
right common carotid artery. When the artery was free of surrounding tissue it was properly ligated 
using a 6-0 surgical silk thread. After a recovery period the pups were subjected to a 100 % nitrogen 
environment at 37 °C for 3 min to induce anoxia. (AI group n = 41). The control group was also 
subjected to the surgical procedure; however the artery was exposed but not ligated. These animals 
were not exposed to the anoxia treatment either (Sham group = 42). The mortality rate of the 
procedure was about of 5 %. 
2.3. PEA and OEA treatments 
An hour after the artery ligation and nitrogen exposure (or sham procedures) were finished 
pups were injected intraperitoneally (i.p.) with a DMSO solution [vehicle, n = 9 sham pups (Sham-
Veh) and 10 AI pups (AI-Veh)], 2 mg/kg of OEA [n = 7 sham pups (Sham-O2) and n = 7 AI pups (AI-
O2)], 10 mg/kg of OEA [n = 9 sham pups (Sham-O10) and n = 9 AI pups (AI-O10)], 2 mg/kg of PEA [n 
= 7 sham pups (Sham-P2) and n = 7 AI pups (AI-P2)], and 10 mg/kg of PEA [n = 9 sham pups (Sham-
P10) and n = 9 AI pups (AI-P10)]. Pups were pseudo-randomly assigned to each group and these 
were composed by pups from at least three different dams. Twenty-three days after the carotid 
ligation treatment (or sham procedures), animals were subjected to a battery of behavioral tests and 
then euthanized and brains collected for immunohistochemistry analysis.  
2.4. Behavioral assessment 
When rats were 30 days old 7-10 animals from each of the groups were subjected to a 
number of behavioral tests (Elevated Plus Maze, Open Field, Object Recognition, Morris Water Maze 
and Passive Avoidance tests). Every animal was subjected to a period of handling prior the beginning 
of the behavioral assessment (five minutes per day during three consecutive days). The whole set of 
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tests was carried out during the 12 h of light and soft background noise was provided throughout the 
whole process. Training sessions were recorded (JVC Everio GZHD620 camcorder) and analyzed 
using a computerized video-tracking system (ANY-maze, Stoelting Co., Wood Dale, IL) or with the 
ethological software J WatcherV1.0. 
2.3.1. Elevated plus maze test 
The elevated plus maze (EPM) test was carried out in a plus shaped device consisting of a 
central platform (11 × 11 cm) and four equally long arms: two open (50 × 11 × 0.25 cm) arms and two 
arms surrounded by walls (50 × 11 × 40 cm) (Galeano et al. 2015). The device was set 100 cm above 
the floor. The apparatus was evenly illuminated with an intensity measured in open arms of 85–90 lux. 
For each trial the animal was placed in the middle of the device facing one of the open arms. Animals 
were left to explore the apparatus for 5 min. An entry to an arm was counted when the rat set all four 
paws into one arm. Total distance covered, number of times the animal entered a closed arm, 
percentage of open arm entries (open arm entries/total entries × 100) and percentage of time spent in 
open arms (time spent in open arms/300 × 100) were recorded. 
2.3.2. Open field test 
For the open field (OF) test an evenly illuminated black arena was utilized (60 × 60 cm and 40 
cm high) (Galeano et al. 2015). In order to delimit the central and most illuminated area (70 lux) of the 
arena an imaginary square of 30 × 30 cm was drawn over the image of the apparatus during the data 
analysis. Animals were carefully set in the apparatus and left to explore it for 10 min. An animal was 
considered to be in the central area when its four paws were on the delimited 30 x 30 cm square.  
Distance covered, number of rears, number of entries and time spent into the central area were 
recorded in two time bins of 5 min each. 
2.3.3. Novel object recognition test 
The novel object recognition test (NORT) was carried out 24 h following the OF, using the 
same arena. NORT is a widely employed and validated test to assess recognition memory (Ennaceur 
2010; Ennaceur and Delacour 1988). During the test animals were set in the arena where two 
identical objects were placed. Rats were allowed to explore the apparatus and the objects for 5 min 
(sample trial). This trail was followed by a period (1 h) in which animals were returned to their cages. 
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Rats were then returned once more to the arena and were presented with one familiar object and a 
novel one. Animals were given 3 min to explore the objects and then returned to their cages (retention 
trial). The apparatus was evenly illuminated at approximately 70 lux and the device and the objects 
were thoroughly clean between animals. All possible location or object combinations were employed 
to prevent bias due to a preference for a particular object or specific location. Animals were 
considered to be exploring an object when their snout was directed towards it at a distance of 2 cm or 
less. Discrimination index (d1) and ratio (d2) scores were calculated using the following formulas: d1 
= tn -.tf, and d2 = (tn - tf) / (tn - tf), where tn is the amount of time that rats expend exploring the novel 
object and tf is the amount of time rats explored the familiar object. 
2.3.4. Morris water maze test 
For the Morris water maze (MWM) a black steel tank (180 cm diameter; 60 cm deep) filled 
with water at 22 ± 1 °C and a translucent circular platform were used (Galeano et al. 2011, 2015). 
Different visual cues were located on the walls surrounding the maze and the whole setting was 
indirectly illuminated. The tank was divided by the operators in four equal quadrants and the platform 
was set in the middle of one of the quadrants. According to each quadrant, four starting positions 
were determined. Latency to platform, distance to platform and swim speed were registered during 
spatial learning training. In the probe trial, the platform was removed and the percentage of time spent 
in each quadrant and the numbers of crossings over a circular area (with a diameter larger than 
platform diameter) located on the previous platform position were recorded. 
In the cued learning phase, the surrounding visual cues were covered with a black curtain and 
the platform was set 2 cm above water level with a flag attached to it. Eight cued learning trails were 
performed during two day (four each day). The location of the platform and the starting point were 
modified for each trial. If after 60 s the animal had not found the platform it was gently guided to it and 
left there for 15 s. To assess spatial learning and reference memory the black curtain was removed 
and the visual cues were available while the platform was set under water (2 cm below the water 
surface). The test consisted of four trials each day, performed over the period of 6 days. The animal 
was released from one of the starting positions and it was left to explore the maze looking for the 
hidden escape platform (the platform remained in the same location for all the trails). If the animal was 
unable to find the platform after 60 s it was guided to it and left there for 15 s. During each trial the 
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starting position was changed and the sequence used varied along the 6 days of the test. Reference 
memory was assessed 24 h after the last learning trail with a probe trial of 60 s. For this probe trial the 
animal was released from a novel starting position and the platform was removed from the maze. 
2.3.5. Passive avoidance 
The passive avoidance test was used to assess associative memory (Deacon et al. 2002). The 
device consisted of a box (60 cm × 60 cm × 40 cm) divided in two. The resulting compartments were 
both 30 cm long and separated by a door that opened sliding into the floor. One of the compartments 
was made of white plastic and well illuminated. The second compartment was dim and made of dark, 
electrifiable metal. During the acquisition phase the rat was placed in the light compartment and it was 
allowed to freely explore de devise. The moment the animal crossed into the black compartment it 
received a mild foot shock (1.2 mA, 2 s duration) and it was promptly removed from the device. One 
hour later, the retention trial took place and the rat was again placed in the white compartment and 
was left to freely explore the entire apparatus during a maximum of 10 min (no foot shock was 
delivered once it entered the dark compartment). The ratio between the latency of the rat to move into 
the dark compartment in the retention trial (T2) and in the training sessions (T1) was taken as a 
measure of associative memory retention (T2/T1) (Deacon et al. 2002).  
2.4. Tissue processing 
After the behavioral assessment was finished, 4-5 randomly chosen rats per group were 
administered with a mixture of 40 mg/kg ketamine and 4 mg/kg xylazine and subjected to an 
intracardiac perfusion, firstly with saline solution (0.9 % Sodium Chloride) with 1 % (v/v) heparin in 
order to clean the tissues, and finally with cold 4 % formaldehyde solution (freshly made from 
paraformaldehyde; Sigma-Aldrich, St. Louis, MO, USA). When the tissue was properly fixated the 
brain was carefully extracted and post fixed in formaldehyde solution for 2 h at 4 °C. Finally, 40-μm-
thick coronal sections were obtained from each brain and they were properly stored in a 0.002 % 
(w/v) NaN3 solution at 4 °C. 
2.5. Immunohistochemical procedures 
The presence of markers related to neuroinflammation, astrogliosis and the expression of 
PPARα were assessed using immunohistochemistry. For this purpose sections from each group were 
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placed in separate wells in a 24 well plate. Samples were washed 5 times for 10 min using 0.1 M 
phosphate buffer solution with 0.5 % Tween 20 (PBS-T), at room temperature (RT) in order to 
properly eliminate the formaldehyde that was used as a fixative agent. To block the endogenous 
peroxidase, sections were incubated with 30 % H2O2 in PBS during 30 min at RT. Samples were then 
washed 5 times for 10 min with PBS-T and unspecific antigens were blocked incubating the sections 
in 4 % BSA (Bovine Serum Albumin), diluted in PBS-T, for 1 h at RT. Afterwards samples were 
washed 5 times for 10 min with PBS-T and then incubated with the corresponding primary antibody 
[rabbit anti-Iba-1 (1:1000, Wako, Osaka, Japan; cat. no. 019-19741; mouse anti-GFAP (1:500, 
G3893, Sigma; rabbit anti-PPARα (1:100, P11120812, Fitzgerald)] over night at 4 °C. The following 
day samples were washed 5 times for 10 min using PBS-T and subsequently incubated with 
horseradish-peroxidase (HRP) biotinylated secondary antibody (donkey anti-rabbit IgG, 5356499, GE 
Healthcare; goat anti-mouse IgG, 125K6063, Sigma) for 2 h at RT. Once the two hours had elapsed, 
samples were again washed 5 times for 10 min with PBS-T and incubated with ABC (Avidin-Biotin 
complex) solution (1:1000; ExtrAvidin peroxidase, Sigma, St Louis, MO, USA) for 1 h in darkness at 
RT. The ABC solution was washed 5 times for 10 min using PBS-T. Finally the signal was detected 
using 0.05 % diaminobenzidine (DAB; Sigma) diluted in PBS containing 0.03 % H2O2. Sections were 
then washed several times using running water, mounted on slides treated with poly-L-lysine solution 
(Sigma) and subjected to a process of dehydration (increasing ethanol concentration followed by 
xylene). Samples were covered with cover slips using Eukitt mounting medium (Kindler GmBH & Co., 
Freiburg, Germany). After they were dry, samples were observed using an Olympus BX41 
Microscope coupled with an Olympus DP70 digital camera (Olympus, Germany) or an Olympus BX60 
microscope coupled to Olympus DP71 digital camera (Olympus, USA). All the photographs were 
taken under the same conditions of light and brightness/contrast. 
2.6. Immunohistochemical quantification 
Four to seven coronal sections from Bregma levels -3.14 to -4.30 mm (dorsal hippocampus) 
(Paxinos 2007), from each animal, were selected and employed for immunohistochemical analysis. 
Quantification was carried out using the “Cell counter” plug in tool from Image J software (NIH, USA). 
Images were changed to binary code and the area of interest delimited. For Iba-1 and GFAP 
quantification, 0.08 mm2 squares were set and distributed so that each area of the hippocampus 
studied (CA1, CA3 and DG) was properly represented, while 0.02 mm2 squares were employed in the 
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case of PPARα. The number of positive cells was manually determined in each square and averaged 
to determine the number of cells per mm2. Quantifications were made by experimenters blinded to 
treatments. 
2.7. Statistics analysis 
Behavioral and immunohistochemical data were analyzed by one or two-way ANOVA tests, 
followed by Tukey's post hoc multiple comparison tests. Moreover, one sample t-tests were employed 
when it was required. A probability equal or less than 5 % was accepted as statistically significant and 
always two-sided probabilities were reported. Data are expressed as mean ± SEM.  
3. Results 
3.1. Neonatal anoxia-ischemia reduces exploratory activity without modifying anxiety-like 
behaviors in the EPM and OF tests 
3.1.1. Elevated plus maze test 
When the distance covered was analyzed, a two-way ANOVA test revealed that the main factor 
Postnatal condition was significant (F(1, 73) = 40.7, p < 0.001), while neither the main factor Treatment 
nor the interaction Postnatal condition x Treatment were significant (F(4, 73) = 1.4, p = n.s.; F(4, 73) < 1, p 
= n.s.). Similarly, in the case of closed arms entries, the main factor Postnatal condition was 
significant (F(1, 73) = 16.2, p < 0.001), while neither the main factor Treatment nor the interaction 
Postnatal condition x Treatment were significant (F(4, 73) < 1, p = n.s.; F(4, 73) < 1, p = n.s.). These 
results indicate that rats that were subjected to anoxia-ischemia, regardless of the treatment received, 
covered a significantly lower distance and visited significantly fewer times the closed arms in 
comparison with sham groups (see Fig. 1A-B). Regarding anxiety-related behaviors, none of the 
groups differed neither in the percentage of open arms entries nor in the percentage of time in open 
arms (Percentage of open arms entries: Postnatal condition, F(1, 73) < 1, p < n.s.; Treatment, F(4, 73) < 1, 
p = n.s.; Postnatal condition x Treatment, F(4, 73) < 1, p = n.s. Percentage of time in open arms: 
Postnatal condition, F(1, 73) < 1, p = n.s.; Treatment, F(4, 73) < 1, p = n.s.; Postnatal condition x 
Treatment, F(4, 73) < 1, p = n.s.) (see Fig. 1C-D). 
3.1.2. Open field test 
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Two-way mixed ANOVA test revealed that the main factors Group and Time, and the 
interaction Group x Time were all significant (F(9, 146) = 4.4, p < 0.001; F(1, 146) = 132.4, p < 0.001; F(9, 
146) = 3.2, p = 0.001, respectively), in the case of distance covered. Post-hoc multiple comparison 
Tukey tests showed that rats subjected to anoxia-ischemia covered a significantly lower distance than 
sham groups during the first five minutes (see Fig. 2A). All the groups significantly reduced their 
distance covered to the same levels during the second five minutes compared with the first five 
minutes, indicating that every group showed a normal habituation response (see Fig. 2A). When the 
number of rears was analyzed, the two-way ANOVA tests revealed that the main factors Groups and 
Time were significant (F(9, 146) = 2.7, p = 0.005; F(1, 146) = 11.2, p = 0.001, respectively), while the 
interaction Group x Time was not (F(9, 146) < 1, p = n.s.). These results indicate that rats subjected to 
anoxia-ischemia displayed a significantly lower number of rears across the entire test compared with 
sham groups and that all groups showed a significantly lower number of rears during the second five 
minutes than during the first five minutes (see Fig. 2B). Finally, none of the groups presented 
differecens in anxiety-related behaviors (Entries into the center: Group, F(9, 146) = 1.6, p = n.s.; Time, 
F(1, 146) = 2.1, p = n.s.; Group x Time, F(9, 146) < 1, p = n.s. Time in central area: Group, F(9, 146) < 1, p = 
n.s.; Time, F(1, 146) = 1.1, p = n.s.; Group x Time, F(9, 146) < 1, p = n.s.) (see Fig. 2C-D).  
3.2. Palmitoylethanolamide prevents cognitive deficits that follow to neonatal anoxia-ischemia 
3.2.1. Novel object recognition test 
One-sample t-tests revealed that in groups of rats subjected to anoxia-ischemia, except in the 
case of AI-P10 group, discrimination index (d1) and discrimination ratio (d2) did not differ from a 
hypothetical 0 value (d1. AI-Veh: t = 0.4, d.f. = 8, p = n.s.; AI-O2: t = 0.8, d.f. = 6, p = n.s.; AI-O10: t = 
0.6, d.f. = 8, p = n.s.; AI-P2: t = 0.5, d.f. = 6, p = n.s. d2. AI-Veh: t = 0.5, d.f. = 8, p = n.s.; AI-O2: t = 
0.6, d.f. = 6, p = n.s.; AI-O10: t = 0.4, d.f. = 8, p = n.s.; AI-P2: t = 0.2, d.f. = 6, p = n.s.) (see Fig. 3A-B). 
On the other hand, sham groups and the AI-P10 group showed significantly higher d1 and d2 than the 
hypothetical 0 value, meaning that they spent more time exploring the novel object than the familiar 
one (d1. Sham-Veh: t = 3.5, d.f. = 9, p = 0.006; Sham-O2: t = 3.3, d.f. = 6, p = 0.013; Sham-O10: t = 
3.4, d.f. = 8, p = 0.008; Sham-P2: t = 5.3, d.f. = 6, p = 0.002; Sham-P10: t = 14.7, d.f. = 8, p < 0.001.; 
AI-P10: t = 5.0, d.f. = 8, p = 0.002. d2. Sham-Veh: t = 4.6, d.f. = 9, p = 0.002; Sham-O2: t = 3.4, d.f. = 
6, p = 0.012; Sham-O10: t = 4.2, d.f. = 8, p = 0.002; Sham-P2: t = 9.7, d.f. = 6, p < 0.001; Sham-P10: t 
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= 9.7, d.f. = 8, p < 0.001; AI-P10: t = 5.6, d.f. = 8, p = 0.001) (see Fig 3A-B). In this test, treatment with 
10 mg/kg of PEA prevented the recognition memory deficit showed by AI groups. 
3.2.2. MWM test: cue learning 
To analyze the performance of animals during the cue learning phase, the latency to reach the 
visible platform was used as the dependent variable. Two-way ANOVA test revealed that the main 
effect of Day was significant (F(1, 146) = 50.8, p < 0.001), while neither the main effect of Group nor the 
interaction Day x Group were (F(9, 146) < 1, p = n.s. for both cases) (see Fig. S1). These results mean 
that all groups significantly reduced their escape latency from one day to another, indicating the 
absence of visual or motor impairments and a similar level of motivation between the groups to solve 
the task. 
3.2.3. MWM test: spatial learning and reference memory 
To evaluate spatial memory, the dependent values latency to platform, distance to platform and 
swim speed were analyzed by two-way ANOVA tests. Results indicated that, in the three cases, the 
main factor Day was significant (Latency: F(5, 438) = 92.4, p < 0.001; Distance: F(5, 438) = 115.3, p < 
0.001; Speed: F(5, 438) = 33.5, p < 0.001), while neither the main factor Group nor the interaction Group 
x Day were significant (Group: Latency, F(9, 438) < 1, p = n.s.; Distance: F(9, 438) = 1.1, p = n.s.; Speed, 
F(9, 438) < 1, p = n.s. Group x Day: Latency, F(45, 438) < 1, p = n.s.; Distance: F(45, 438) < 1, p = n.s.; 
Speed, F(45, 438) < 1, p = n.s.). These results show that all groups, regardless of treatment, significantly 
reduced their latency, distance and swim speeds at the same rate across days of learning (see Fig. 
4A-C). 
When time spent in the target quadrant (the quadrant where the platform was located during 
the spatial learning phase) was analyzed during the probe trial, one-sample t-tests revealed that 
groups of rats subjected to anoxia-ischemia, except the AI-P10 group, spent a not significantly 
different percentage of time than expected by chance in this area (25 %, dashed line) (AI-Veh: t = 1.0, 
d.f. = 8, p = n.s.; AI-O2: t = 1.3, d.f. = 6, p = n.s.; AI-O10: t = 1.6, d.f. = 8, p = n.s.; AI-P2: t = 1.3, d.f. = 
6, p = n.s.) (see Fig. 5A). By contrast, sham groups, regardless of treatments, and the AI-P10 group 
spent significantly higher percentages of time in the target quadrant than expected by chance (Sham-
Veh: t = 5.8, d.f. = 9, p < 0.001; Sham-O2: t = 4.2, d.f. = 6, p = 0.005; Sham-O10: t = 8.8, d.f. = 8, p < 
0.001; Sham-P2: t = 5.1, d.f. = 6, p = 0.002; Sham-P10: t = 8.3, d.f. = 8, p < 0.001; AI-P10: t = 5.3, d.f. 
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= 8, p < 0.001) (see Fig. 5A). A similar pattern of results was obtained when the numbers of crossings 
over a circular area larger than the platform area were analyzed. The two-way ANOVA test indicated 
that the main factor Postnatal condition was significant (F(1, 73) = 29.4, p < 0.001), while neither the 
main factor Treatment nor the interaction Postnatal condition x Treatment were significant (F(4, 73) = 
1.9, p = n.s.; F(4, 73) = 1.7, p = n.s., respectively). Although the interaction Postnatal condition x 
Treatment did not reach a significant level, post-hoc multiple comparison Tukey tests showed that 
groups of rats subjected to ischemia-anoxia crossed the circular area significantly less times 
compared with sham and AI-P10 groups (see Fig. 5B). These results indicate that anoxia-ischemia 
was associated with a spatial reference memory deficit that was prevented by the treatment with 
palmitoylethanolamide at a dose of 10 mg/kg. 
3.2.4. Passive avoidance test 
A two-way ANOVA test to analyze the retention index (T2/T1) showed that neither the main 
factor Postnatal condition nor the main factor Treatment nor the interaction Postnatal condition x 
Treatment were significant (F(1, 73) < 1, p = n.s.; F(4, 73) < 1, p = n.s.; F(4, 73) < 1, p = n.s., respectively) 
(see Fig. S2). This result shows that retention index did not differ among groups, indicating that 
associative memory was affected neither by anoxia-ischemia nor by treatment with OEA or PEA. 
3.3. Hippocampal neuroinflammation induced by neonatal anoxia-ischemia is prevented by 
palmitoylethanolamide administration 
When the number of Iba-1 positive cells where analyzed in the CA1 hippocampal area, a two-
way ANOVA test revealed that the main factors Postnatal condition (Sham and AI) and Treatment 
(Veh, O2, O10, P2, P10) and the interaction Postnatal condition x Treatment were all significant (F(1, 
33) = 103.9, p < 0.001; F(4, 33) = 7.7, p < 0.001; F(4, 33) = 3.0, p = 0.031, respectively). Post-hoc multiple 
comparisons Tukey tests indicated that all groups of rats submitted to neonatal anoxia-ischemia, but 
the group administered with 10 mg/kg of PEA, showed a significantly higher number of Iba-1 positive 
cells compared with sham groups (see Fig 6 and Fig. S3). Moreover, AI-P10 group showed a similar 
number of Iba-1 positive cells compared with sham groups (see Fig 6 and Fig. S3). Finally, it was 
observed that treatment with OEA (2 or 10 mg/kg) or PEA (2 or 10 mg/kg) had no effect on the 
number of Iba-1 positive cells among sham groups (see Fig 6 and Fig. S3). 
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Similarly to what had been seen in the hippocampal CA1 area, two-way ANOVA tests revealed 
that the main factors Postnatal condition and Treatment and the interaction Postnatal condition x 
Treatment were all significant when the number of Iba-1 positive cells were analyzed in CA3 and DG 
areas (CA3: F(1, 33) = 156.0, p < 0.001; F(4, 33) = 13.9, p < 0.001; F(4, 33) = 3.7, p = 0.013, respectively; 
DG: F(1, 33) = 94.3, p < 0.001; F(4, 33) = 11.5, p < 0.001; F(4, 33) = 16.9, p < 0.001, respectively). Post-hoc 
analysis also indicated that, in both hippocampal areas, the number of Iba-1 positive cells was 
significantly higher in the AI groups compared with sham groups, except in the case of the AI-P10 
which showed a similar number of Iba-1 positive cells to sham groups (see Fig 6 and Fig. S3). Finally, 
neither in the CA3 area nor in the DG area, sham groups differed in their number of Iba-1 positive 
cells (see Fig 6 and Fig. S3). 
3.4. Neonatal anoxia-ischemia induces an astrogliosis response that is partially reverted by 
palmitoylethanolamide treatment 
To analyze the number of GFAP positive cells in the three areas of the hippocampus studied 
(CA1, CA3 and DG), two-way ANOVA tests were performed and results revealed that the main factor 
Postnatal condition and the interaction Postnatal condition x Treatment were both significant (CA1: 
F(1, 33) = 97.3, p < 0.001; F(4, 33) = 4.3, p = 0.007, respectively. CA3: F(1, 33) = 112.4, p < 0.001; F(4, 33) = 
3.6, p = 0.014, respectively. DG: F(1, 33) = 69.8, p < 0.001; F(4, 33) = 3.1, p = 0.029, respectively). The 
main factor Treatment was not significant in any of the three hippocampal areas (CA1: F(4, 33) = 1.7, p 
= n.s. CA3: F(4, 33) = 1.0, p = n.s. DG: F(4, 33) = 1.6, p = n.s.). 
In the CA1 area, the analyses of simple effects by post-hoc Tukey tests indicated that AI 
groups, except the AI-P10 group, showed a significantly higher number of GFAP positive cells 
compared with sham groups (see Fig 7 and Fig. S4). The AI-P10 showed a number of GFAP positive 
cells that were not significantly different in comparison with sham groups and the AI-P2 group (see 
Fig 7 and Fig. S4). In the CA3 area, AI-Veh, AI-O2, AI-O10 and AI-P2 showed a significantly higher 
number of GFAP positive cells compared to sham group, while AI-P10 showed a significantly higher 
number of GFAP positive cells in comparison with the Sham-Veh group and significantly lower 
number compared with AI-Veh and AI-O10 groups (see Fig 7 and Fig. S4) Finally, in the DG, AI 
groups, except for the AI-P10 group, showed a significantly higher number of GFAP positive cells 
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compared with the sham groups, while the AI-P10 group did not significantly differed from the sham 
group  and the remaining AI groups in the number of GFAP positive cells (see Fig 7 and Fig. S4). 
3.5. Neonatal anoxia-ischemia is associated with a reduced PPARα expression 
Two-way ANOVA tests revealed that the main effect of Postnatal condition was significant in all 
hippocampal areas when the number of PPARα was analyzed (CA1: F(1, 33) = 12.5, p = 0.01. CA3: F(1, 
33) = 16.5, p < 0.001. DG: F(1, 33) = 24.5, p < 0.001), while the main effect of Treatment and the 
interaction Postnatal condition x Treatment did not reach significance levels (Treatment: CA1: F(4, 33) = 
1.2, p = n.s.; CA3: F(4, 33) = 1.3, p =n.s.; DG: F(4, 33) = 2.4, p = n.s. Postnatal condition x Treatment: 
CA1: F(4, 33) < 1, p = n.s.; CA3: F(4, 33) < 1, p = n.s.; DG:. F(4, 33) < 1, p  = n.s.). Overall, statistical results 
indicate that AI groups, regardless of the treatment received, showed a significantly lower number of 
PPARα positive cells compared with sham groups (see Fig 8 and Fig. S5). 
4. Discussion 
In the present work we studied the potential neuroprotective effects of PEA and OEA on the 
hippocampus of animals exposed to neonatal AI. For this purpose, an array of behavioral tests and 
immunohistochemical analysis were performed. In the EPM and OF tests we were able to observe 
that animals exposed to AI showed a lower response to novelty, while no changes in anxiety-like 
behaviors were detected. Furthermore, recognition and spatial reference memory impairments were 
detected in NORT and MWM tests. These memory deficits were prevented by PEA treatment, while 
OEA administration had no detectable effects. In addition, neonatal AI was associated with an 
increased number of Iba-1 and GFAP positive cells in the hippocampus, a critical area for memory 
processing and especially vulnerable to AI (Dai et al. 2017; Zhu et al. 2018). These neurobiological 
alterations could be, in part, responsible for the cognitive deficits observed, since PEA treatment was 
also able to prevent neuroinflammation and reduce astrogliosis. Although the neuroprotective effects 
of PEA have been studied in animal models of brain injury (Ahmad et al. 2012; D'Agostino et al. 2012; 
Esposito et al. 2012; Schomacher et al. 2008; Scuderi et al. 2018), as far as we know this is the first 
time that the neuroprotective properties of PEA are reported in a neonatal model of AI. 
4.1. Neonatal AI is associated with reduced novelty response but not with anxiety-related 
behaviors 
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During the EPM and OF tests we found that animals subjected to AI present a lower number of 
entries to the closed arms (locomotion indicator) as well as a decrease in the total distance covered. 
This effect in locomotion could be attributed to a decrease in the response to novelty since in the OF 
we only observed this change in locomotion during the first 5 min of the test, while every group 
presented a normal response to habituation. We, as well as others, have already observed this lower 
curiosity/motivation to explore novel environments in another model of hypoxia-ischemia (Galeano et 
al. 2011; Strackx et al. 2010), which suggests that this effect could be related to underlying brain 
processes altered by oxygen deprivation rather than other mechanisms triggered by a specific animal 
model. 
It is important to note that, unlike other authors (Ming-Yan et al. 2012; Sedláčková et al. 2014), 
we did not find changes in anxiety-related behaviors. However, this is consistent with previous results 
from our group in another model of global hypoxia-ischemia (Galeano et al. 2011). We could then 
hypothesize that these discrepancies may be related to intrinsic differences between animal models 
of neonatal ischemia. Since the model employed in the present work has been recently validated, 
effects such as this should be noted for further studies. 
4.2. PEA treatment prevents memory impairments induced by neonatal AI 
Animals exposed to AI showed recognition and spatial reference memory impairments, while 
associative memory was altered neither by AI nor by pharmacological treatments. Previous works 
have already found an association between alterations in both NORT and MWM tests and AI (Almli et 
al. 2000; Barros et al. 2009; Balduini et al. 2000; Cechetti et al. 2010; Cunha-Rodrigues et al. 2018; 
Domnick et al. 2015; Griva et al. 2017; Pereira et al. 2007). For example, Cunha-Rodrigues et al. 
(2018) found that pups whose mothers had been subjected to uterine artery ligation showed a 
recognition memory deficit concomitant with loss of hippocampal neurons. Moreover, Domnick et al. 
(2015) observed similar results in 2-day-old rat pups subjected to common carotid artery ligation. 
Regarding spatial memory, Griva et al. (2017) observed that animals subjected to left common carotid 
artery ligation followed by 60 min of hypoxia (8% O2) showed an impaired performance in the MWM. 
Similarly, Cechetti et al. (2010) had already found that animals exposed to bilateral occlusion of the 
common carotid arteries (2VO) present deficits in spatial memory. In the present work, we were able 
to observe that treatment with 10 mg/kg of PEA, administered one hour after AI, prevented 
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recognition and reference memory deficits. So far, exogenous administration of PEA has shown to be 
capable of preventing memory deficits in animal models of Alzheimer’s disease (D'Agostino et al. 
2012; Scuderi et al. 2014, 2018). Regarding associative memory, similarly to what was reported by 
Balduini et al. (2000), we did not observe differences between sham and AI groups, suggesting that 
AI has no effects on this type of memory. This results extent the previously observed neurobehavioral 
beneficial effects of PEA to an ischemia model, and suggest that PEA could be used as a potential 
treatment against memory impairments induced by different types of brain injuries. 
4.3. Neuroinflammation and astrogliosis induced by AI is partially prevented by PEA treatment 
In the present work we observed a decrease in PPARα levels in animals subjected to AI, 
which is consistent with previous results from our group (Blanco et al. 2015; Holubiec et al. 2017). 
Furthermore, the results obtained in the present study show that there is an increase in 
neuroinflammation (Iba-1) and astrogliosis (GFAP) in animals subjected to AI. 
It has already been shown that AI leads to inflammation in different parts of the CNS (Driscoll 
et al. 2018). During recent years the role that microglia plays in disorders of the CNS has been 
thoroughly studied (Crews et al. 2017; Salter and Stevens 2017). Microglia has been shown to be 
involved in different processes such as regulation of embryonic vasculogenesis, secretion of trophic 
factors, immuno-surveillance, oligodendrogenesis and neurogenesis (Mallard et al. 2018). It has been 
observed that neuroinflamation due to hypoxia-ischemia plays a key and deleterious role in this event 
(Galinsky et al. 2018). The production of different factors such as IL-18, Caspase-1 and TGF-β has 
been proven to be related to damages caused by microglia in animals exposed to AI (Chen et al. 
2018; Mallard et al. 2018). Cunha-Rodrigues et al. (2018) has described oligodendrocyte loss, 
astrogliosis and neuronal death due to HI. It has also been shown that animals subjected to 
hypoxemia present astrogliosis 6 months post-injury (Davies et al. 2018). Furthermore, it has been 
previously observed that neuroinflamation and astrogliosis hold a close relation to deficits in 
recognition memory (Cunha-Rodrigues et al. 2018; Liaury et al. 2014) and spatial memory (Mirahmadi 
et al. 2017; Pei and Sun 2018). Liaury et al. (2014) has found that microglial activation correlates with 
schizophrenia-like behaviors. Thus, we propose that the neuroinflamation and astrogliosis that we 
observed after AI could be resposable, in part, of the memory deficits that followed AI.  
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Regarding the treatment with PEA, it has already been demonstrated that this ethanolamide 
reduces neuroinflamation and presents a neuroprotective activity in rodents (Di Marzo and Skaper 
2013; Petrosino and Di Marzo 2017; Sayd et al. 2014; Scuderi et al. 2014). For instance, in a rat 
model of Alzheimer’s disease induced by the administration of intrahippocampal beta amyloid 1-42, a 
later treatment with PEA proved to be effective reducing neuroinflamation and exerting 
neuroprotective actions (Scuderi et al. 2014). Furthermore, PEA was shown to promote neuronal 
survival in the hippocampus, normalize astrocytic function and balance glutamatergic transmission, 
thus leading to an improvement in memory impairments (Scuderi et al. 2018). In the present study we 
show that the increase in neuroinflammation and astroglyosis were partially reverted in animals 
treated with 10 mg/kg of PEA. Since PEA also showed a preventive effect regarding the memory 
deficits observed, we propose that these two phenomena may be closely related. 
5. Conclusions 
In the present work we show that AI is associated with recognition and spatial memory 
impairments in a new model of neonatal AI. We have also found that these memory deficits may be 
related to neuroinflammation and astrogliosis in the hippocampus, since PEA treament partially 
reversed this alterations and it was able to prevent memory impairments. Although PEA has shown to 
posses neuroprotective effects in different types of brain injuries, as far as we know this is the first 
time that these neuroprotetive effects of PEA are observed in a neonatal AI model. Overall, these 
results indicate that PEA could be a good candidate to focus on in further studies related to AI, a 
traumantic and not so uncommon event for which effective treatments are lacking. 
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Figures legends 
Figure 1. Exploratory activity and anxiety-related behaviors in the EPM test. a) Distance 
covered, b) Closed arm entries, c) Percentage of open arms entries, d) Percentage of time in open 
arms. Locomotor activity was reduced in AI groups. No differences in anxiety-related behaviors were 
observed between groups. Sham-Veh, Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated 
rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. AI-
Veh, AI-O2, AI-O10, AI-P2, AI-P10: anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 
mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. Symbols and lines depict the mean ± SEM of 7-10 
rats/group. ***p < 0.01. 
Figure 2. Exploratory activity and anxiety-related behaviors in the OF test. a) Distance covered, 
b) Number of rears, c) Entries into the center, d) Time in central area. Locomotor activity was reduced 
in AI groups during their first five minutes of exposition to OF. No differences in anxiety-related 
behaviors were observed between groups. Sham-Veh, Sham-O2, Sham-O10, Sham-P2, Sham-P10: 
sham operated rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, 
respectively. AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: anoxic-ischemic rats treated with vehicle, OEA 2 
mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. Symbols and lines depict the mean 
± SEM of 7-10 rats/group. *p < 0.05 vs. AI groups; ##p < 0.01 ###p < 0.001 vs. first five minutes. 
Figure 3. Palmitoylethanolamide treatment prevents recognition memory impairment 
associated to neonatal anoxia-ischemia. a) Discrimination index (d1) and b) discrimination ratio 
(d2). One sample t-tests: ***p < 0.001, **p < 0.01, *p < 0.05 vs. d1 and d2 values expected when both 
objects (familiar and novel) are explored the same amount of time (0 in both cases). Sham-Veh, 
Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, 
OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: 
anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, 
respectively. Bars depict the mean ± SEM of 7-10 rats/group. 
Figure 4. Spatial learning in the MWM. a) Latency to platform, b) Distance to platform, c) Swim 
speed. Latency, distance and swim speed decreased similarly across days of training, indicating that 
all groups acquired the task at the same rate across days of training. Sham-Veh, Sham-O2, Sham-
O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, 
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PEA 2 mg/kg, PEA 10 mg/kg, respectively. AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: anoxic-ischemic 
rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. 
Symbols and lines depict the mean ± SEM of 7-10 rats/group. 
Figure 5. Spatial reference memory deficit induced by neonatal anoxia-ischemia is prevented 
by palmitoylethanolamide treatment. a) Percentage of time spent in the target quadrant during the 
probe trial. ***p < 0.001, **p < 0.01 vs. percentage of time expected by chance (25 %, dashed line). b) 
Circular area crossing during the probe trial. *p < 0.05, ** p < 0.01 vs. sham groups and AI-P10 group. 
Bars depict the mean ± SEM of 7-10 rats/group. c) Contingency plots. Sham-Veh, Sham-O2, Sham-
O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, 
PEA 2 mg/kg, PEA 10 mg/kg, respectively. AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: anoxic-ischemic 
rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively. 
Figure 6. Immunohistochemical expression of Iba-1 in the hippocampus. a) Representative 
photomicrographs of Iba-1 immunostaining in the hippocampus. Scale bars: 15 μm. 
(Photomicrographs of sham groups treated with OEA (2 and 10 mg/kg) and PEA (2 and 10 mg/kg) 
can be found in Fig. S3). b-d) Quantification of Iba-1 positive cells across layers of the hippocampus 
(CA1, CA3 and DG). Bars depict mean ± SEM of 4-7 sections/rat from groups of 4-5 rats. Sham-Veh, 
Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, 
OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively; AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: 
anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, 
respectively. SO: Stratum oriens; SP: Stratum pyramidale; SR: Stratum radiatum; SL-M: stratum 
lacunosum molecular; ml: molecular cell layer; gcl: granular cell layer; pcl: polymorphic cell layer. *p < 
0.05; **p < 0.01 and ***p < 0.001 vs. sham-operated groups. 
Figure 7. Immunohistochemical expression of GFAP in the hippocampus. a) Representative 
photomicrographs of GFAP immunostaining in the hippocampus. Scale bars: 15 μm. 
(Photomicrographs of sham groups treated with OEA (2 and 10 mg/kg) and PEA (2 and 10 mg/kg) 
can be found in Fig. S4). b-d) Quantification of GFAP positive cells across layers of the hippocampus 
(CA1, CA3 and DG). Bars depict mean ± SEM of 4-7 sections/rat from groups of 4-5 rats. Sham-Veh, 
Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated rats treated with vehicle, OEA 2 mg/kg, 
OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively; AI-Veh, AI-O2, AI-O10, AI-P2, AI-P10: 
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anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, 
respectively. SO: Stratum oriens; SP: Stratum pyramidale; SR: Stratum radiatum; SL-M: stratum 
lacunosum molecular; ml: molecular cell layer; gcl: granular cell layer; pcl: polymorphic cell layer. *p < 
0.05; **p < 0.01 and ***p < 0.001 vs. sham-operated groups; #p < 0.05 vs. AI-P10 group; $p < 0.05 vs. 
Sham-Veh group. 
Figure 8. Immunohistochemical expression of PPARα in the hippocampus. a) Representative 
photomicrographs of PPARα immunostaining in the hippocampus. Scale bars: 15 μm. 
(Photomicrographs of sham groups treated with OEA (2 and 10 mg/kg) and PEA (2 and 10 mg/kg) 
can be found in Fig. S5). b-d) Quantification of PPARα positive cells across layers of the 
hippocampus (CA1, CA3 and DG). Bars depict mean ± SEM of 4-7 sections/rat from groups of 4-5 
rats. Sham-Veh, Sham-O2, Sham-O10, Sham-P2, Sham-P10: sham operated rats treated with 
vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 mg/kg, PEA 10 mg/kg, respectively; AI-Veh, AI-O2, AI-
O10, AI-P2, AI-P10: anoxic-ischemic rats treated with vehicle, OEA 2 mg/kg, OEA 10 mg/kg, PEA 2 
mg/kg, PEA 10 mg/kg, respectively. SO: Stratum oriens; SP: Stratum pyramidale; SR: Stratum 
radiatum; SL-M: stratum lacunosum molecular; ml: molecular cell layer; gcl: granular cell layer; pcl: 
polymorphic cell layer. **p < 0.01 and ***p < 0.001. 
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